Vitamin K2, Osteocalcin, and Insulin Sensitivity

One of the most surprising discoveries in 21st-century endocrinology is that the skeleton is not a passive structural organ but an active endocrine gland. The protein responsible is osteocalcin — the same vitamin K-dependent bone protein that drives skeletal mineralization. Work led by Gerard Karsenty at Columbia (Lee et al., Cell 2007; Ferron et al., Cell 2010) showed that osteocalcin, when released from bone in its undercarboxylated form, acts as a hormone that travels to the pancreas to stimulate insulin secretion and to adipose tissue to stimulate adiponectin production. This puts Vitamin K2 at the center of a paradox: K2 carboxylates osteocalcin and locks it into bone, yet observational and small interventional studies show K2 supplementation improves insulin sensitivity in humans. The resolution involves total-osteocalcin pool size, the dynamic balance between carboxylated and undercarboxylated forms, and K2's anti-inflammatory effects that independently improve insulin signaling. This page walks through the Karsenty mechanism, the Choi and Yoshida human trials, the epidemiological diabetes-risk reductions, and the practical implications for metabolic syndrome and prediabetes management.

Table of Contents

  1. Osteocalcin as a Hormone — The Karsenty Discovery
  2. Pancreatic Beta-Cell Mechanism
  3. Adiponectin and Adipose Tissue Effects
  4. The K2 Paradox — Carboxylation vs Hormone Activity
  5. Choi MK-7 Insulin Sensitivity Trial (2011)
  6. Yoshida Vitamin K and Insulin Resistance (2008)
  7. Epidemiology — K Intake and Type 2 Diabetes Risk
  8. Anti-Inflammatory Pathway to Insulin Sensitivity
  9. Practical Protocol for Metabolic Syndrome and Prediabetes
  10. Cautions & Contraindications
  11. Key Research Papers
  12. Connections

1. Osteocalcin as a Hormone — The Karsenty Discovery

Until the mid-2000s, osteocalcin was understood as a purely structural protein: synthesized by osteoblasts, carboxylated by vitamin K, and embedded into the hydroxyapatite bone mineral matrix where it remained inert until released decades later during bone resorption.

The transformation began with Gerard Karsenty's lab at Columbia University. Lee et al. (2007, Cell 130:456–469) showed that mice genetically lacking osteocalcin developed glucose intolerance, insulin resistance, fat accumulation, and reduced beta-cell mass. Conversely, mice engineered to have excess undercarboxylated osteocalcin showed improved insulin sensitivity, increased beta-cell proliferation, and resistance to diet-induced obesity. doi:10.1016/j.cell.2007.05.047

The critical detail: it was the undercarboxylated osteocalcin (ucOC) that had hormone activity, not the carboxylated form. Carboxylated osteocalcin (the form embedded in bone hydroxyapatite) was metabolically inert. The undercarboxylated form — previously considered a defect, a marker of vitamin K deficiency — turned out to be the active hormone.

This was confirmed by Ferron et al. (2010, Cell 142:296–308), who showed that bone-resorption-induced acidification of the bone matrix locally decarboxylates osteocalcin during osteoclastic activity, releasing the bioactive uncarboxylated form into circulation. The osteoclast itself decarboxylates osteocalcin as part of its normal bone-resorption activity. doi:10.1016/j.cell.2010.06.003

This redefined osteocalcin: it is a hormone produced by osteoblasts, deposited into the bone matrix where it remains inert, and then decarboxylated and released into circulation by osteoclastic bone resorption. The skeleton became an endocrine organ that uses the rate of bone turnover to communicate with the pancreas and adipose tissue.

Back to Table of Contents

2. Pancreatic Beta-Cell Mechanism

The undercarboxylated osteocalcin (ucOC) hormone reaches the pancreas via the bloodstream and acts on a specific G-protein-coupled receptor called GPRC6A, expressed on pancreatic beta cells. Activation of GPRC6A produces several beta-cell effects:

The net result: more insulin available, more beta cells, better insulin secretion in response to meals. The skeleton is functionally regulating glucose homeostasis through the osteocalcin-pancreas axis.

Back to Table of Contents

3. Adiponectin and Adipose Tissue Effects

ucOC also acts on adipose tissue, where it stimulates production of adiponectin. Adiponectin is the most insulin-sensitizing hormone produced by fat tissue — higher adiponectin levels correlate strongly with lower fasting glucose, lower insulin resistance (HOMA-IR), reduced cardiovascular risk, and lower visceral adiposity.

The osteocalcin–adiponectin axis is one of the most elegant endocrine feedback loops yet described. As osteocalcin levels rise (more bone turnover, more undercarboxylated form released), adiponectin rises, peripheral insulin sensitivity improves, blood glucose falls, and the systemic inflammatory state of metabolic syndrome moderates.

This is also why people with low bone density and bone turnover (such as long-term immobilized patients or people on chronic high-dose glucocorticoids) develop insulin resistance more frequently — reduced bone turnover means less ucOC release, less adiponectin stimulation, worse insulin sensitivity.

Back to Table of Contents

4. The K2 Paradox — Carboxylation vs Hormone Activity

Here is the paradox that puzzled researchers for years: Vitamin K2 supplementation increases osteocalcin carboxylation (the well-established mechanism for bone benefit), which logically should reduce circulating undercarboxylated osteocalcin (the hormone form). Yet K2 supplementation also improves insulin sensitivity in humans. How can both be true?

The current resolution involves several mechanisms operating simultaneously:

The practical conclusion: K2 supplementation appears to improve insulin sensitivity in humans regardless of which mechanism predominates. The carboxylation-paradox is theoretically interesting but does not predict clinical outcomes.

Back to Table of Contents

5. Choi MK-7 Insulin Sensitivity Trial (2011)

The most direct human evidence comes from Choi et al. (2011, Diabetes Care 34:e147), a 4-week randomized double-blind placebo-controlled trial of MK-7 30 mg/day in 33 healthy young men. The MK-7 group showed:

doi:10.2337/dc11-0551

Limitations: small sample size (33 subjects), short duration (4 weeks), healthy young men only (not the prediabetic or metabolic syndrome population that would clinically benefit). The trial is hypothesis-generating, not definitive. But it is the most direct human evidence that K2 supplementation improves insulin sensitivity.

Back to Table of Contents

6. Yoshida Vitamin K and Insulin Resistance (2008)

Yoshida et al. (2008, Diabetes Care 31:2092–2096) conducted a 36-month randomized controlled trial of vitamin K (phylloquinone 500 mcg/day, which the body partially converts to MK-4 via UBIAD1) in 355 older adults (60–80 years). Results in the older men:

doi:10.2337/dc08-0048

Limitations: the sex-specific effect (men only) has not been fully explained. The 36-month duration is appropriately long for chronic metabolic effects.

Back to Table of Contents

7. Epidemiology — K Intake and Type 2 Diabetes Risk

Large prospective cohort studies have examined whether dietary vitamin K intake is associated with diabetes risk:

The epidemiology consistently shows that higher vitamin K intake (particularly K2) is associated with lower diabetes risk, lower insulin resistance markers, and reduced metabolic syndrome prevalence. As always with observational data, residual confounding from other healthy dietary patterns cannot be excluded — people who eat more natto, fermented cheeses, leafy greens, and pastured eggs (K2 sources) tend to eat better overall.

Back to Table of Contents

8. Anti-Inflammatory Pathway to Insulin Sensitivity

Chronic low-grade inflammation is now understood as one of the primary upstream drivers of insulin resistance. Inflammatory cytokines (TNF-alpha, IL-6) directly interfere with insulin receptor signaling in peripheral tissues, producing the cellular insulin resistance that defines metabolic syndrome and type 2 diabetes.

Vitamin K2 has direct anti-inflammatory effects that operate independently of its gamma-carboxylation function:

This anti-inflammatory pathway is probably contributing substantially to the insulin-sensitivity benefits of K2 supplementation observed in human trials — not just the osteocalcin-mediated signaling. It also explains why K2 benefits are observed across diverse populations and clinical contexts, not just bone-density-related populations.

Back to Table of Contents

9. Practical Protocol for Metabolic Syndrome and Prediabetes

For adults with metabolic syndrome, prediabetes, or type 2 diabetes who want to add vitamin K2 as part of an evidence-informed protocol:

Foundation

Augmentation (depending on individual profile)

What to expect

Monitoring

Back to Table of Contents

10. Cautions & Contraindications

Back to Table of Contents

Key Research Papers

  1. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G (2007). Endocrine regulation of energy metabolism by the skeleton. Cell 130(3): 456–469. doi:10.1016/j.cell.2007.05.047
  2. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P, Karsenty G (2010). Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142(2): 296–308. doi:10.1016/j.cell.2010.06.003
  3. Choi HJ, Yu J, Choi H, An JH, Kim SW, Park KS, Jang HC, Kim SY, Shin CS (2011). Vitamin K2 supplementation improves insulin sensitivity via osteocalcin metabolism: a placebo-controlled trial. Diabetes Care 34(9): e147. doi:10.2337/dc11-0551
  4. Yoshida M, Jacques PF, Meigs JB, Saltzman E, Shea MK, Gundberg C, Dawson-Hughes B, Dallal G, Booth SL (2008). Effect of vitamin K supplementation on insulin resistance in older men and women. Diabetes Care 31(11): 2092–2096. doi:10.2337/dc08-0048
  5. Beulens JWJ, van der A DL, Grobbee DE, Sluijs I, Spijkerman AM, van der Schouw YT (2010). Dietary phylloquinone and menaquinones intakes and risk of type 2 diabetes. Diabetes Care 33(8): 1699–1705. doi:10.2337/dc09-1499
  6. Ibarrola-Jurado N, Salas-Salvado J, Martinez-Gonzalez MA, Bullo M (2012). Dietary phylloquinone intake and risk of type 2 diabetes in elderly subjects at high risk of cardiovascular disease. American Journal of Clinical Nutrition 96(5): 1113–1118. doi:10.3945/ajcn.111.033498
  7. Pittas AG, Harris SS, Eliades M, Stark P, Dawson-Hughes B (2009). Association between serum osteocalcin and markers of metabolic phenotype. Journal of Clinical Endocrinology & Metabolism 94(3): 827–832. doi:10.1210/jc.2008-1422
  8. Hwang YC, Jeong IK, Ahn KJ, Chung HY (2009). The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects. Diabetes/Metabolism Research and Reviews 25(8): 768–772. doi:10.1002/dmrr.1045
  9. Iki M, Tamaki J, Fujita Y, Kouda K, Yura A, Kadowaki E, Sato Y, Moon JS, Tomioka K, Okamoto N, Kurumatani N (2012). Serum undercarboxylated osteocalcin levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study. Osteoporosis International 23(2): 761–770. doi:10.1007/s00198-011-1600-7
  10. Pi M, Wu Y, Quarles LD (2011). GPRC6A mediates responses to osteocalcin in beta-cells in vitro and pancreas in vivo. Journal of Bone and Mineral Research 26(7): 1680–1683. doi:10.1002/jbmr.390
  11. Mizokami A, Yasutake Y, Gao J, Matsuda M, Takahashi I, Takeuchi H, Hirata M (2013). Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice. PLoS ONE 8(2): e57375. doi:10.1371/journal.pone.0057375
  12. Manna P, Kalita J (2016). Beneficial role of vitamin K supplementation on insulin sensitivity, glucose metabolism, and the reduced risk of type 2 diabetes: a review. Nutrition 32(7-8): 732–739. doi:10.1016/j.nut.2016.01.011
  13. Shea MK, Booth SL, Massaro JM, Jacques PF, D'Agostino RB Sr, Dawson-Hughes B, Ordovas JM, O'Donnell CJ, Kathiresan S, Keaney JF Jr, Vasan RS, Benjamin EJ (2008). Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. American Journal of Epidemiology 167(3): 313–320. doi:10.1093/aje/kwm306
  14. Knapen MHJ, Jardon KM, Vermeer C (2018). Vitamin K-induced effects on body fat and weight: results from a 3-year vitamin K2 intervention study. European Journal of Clinical Nutrition 72(1): 136–141. doi:10.1038/ejcn.2017.146

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents